| abstract |
Described is a pharmaceutical composition for treating or preventing an allergic reaction associated with increased IgE levels in a mammal comprising compounds of the formula shown, where: X and Y are independently H, alkyl, alkoxy, aryl, substituted aryl, hydroxy, halogen, amino, alkylamino, nitro, cyano, CF3, OCF3, CONH2, CONHR or NHCOR1; R is H, CH3, C2H5, C3H7, C4H9, CH2Ph or CH2C6H4-F(p-); R1 and R2 are independently H, aryl, substituted aryl, cycloaryl, substituted cycloaryl, multi-ring cycloaryl, benzyl, substituted benzyl, alkyl, cycloalkyl, substituted cycloalkyl, multi-ring cycloalkyl, fused-ring aliphatic, cyclopropyl, substituted cyclopropyl, cyclobutyl, substituted cyclobutyl, cyclopentyl, substituted cyclopentyl, cyclohexyl, substituted cyclohexyl, cycloheptyl, substituted cycloheptyl, bicycloheptyl, bicyclooctyl, bicyclononyl, substituted bicycloalknyl, adamantyl, substituted adamantyl or heterocyclic ring; where at least one of R1 and R2 are aromatic groups and where R1 and R2 cannot both be phenyl groups when R is H. The above-described pharmaceutical compositions are useful for treating or preventing allergic reactions associated with increased IgE levels in mammals. The above-described pharmaceutical compositions are useful for treating or preventing asthma in mammals. |